Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models.
Caston RA, Shah F, Starcher CL, Wireman R, Babb O, Grimard M, McGeown J, Armstrong L, Tong Y, Pili R, Rupert J, Zimmers TA, Elmi AN, Pollok KE, Motea EA, Kelley MR, Fishel ML. Caston RA, et al. Among authors: pili r. J Cell Mol Med. 2021 Jan;25(2):784-800. doi: 10.1111/jcmm.16132. Epub 2020 Dec 3. J Cell Mol Med. 2021. PMID: 33274592 Free PMC article.
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP. Radovich M, et al. Among authors: pili r. Oncotarget. 2016 Aug 30;7(35):56491-56500. doi: 10.18632/oncotarget.10606. Oncotarget. 2016. PMID: 27447854 Free PMC article.
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).
Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA. Pili R, et al. Clin Cancer Res. 2017 Dec 1;23(23):7199-7208. doi: 10.1158/1078-0432.CCR-17-1178. Epub 2017 Sep 22. Clin Cancer Res. 2017. PMID: 28939740 Free PMC article. Clinical Trial.
Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma.
Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R. Elbanna M, et al. Among authors: pili r. Mol Cancer Ther. 2020 Jan;19(1):147-156. doi: 10.1158/1535-7163.MCT-18-1202. Epub 2019 Oct 3. Mol Cancer Ther. 2020. PMID: 31582532 Free PMC article.
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.
Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, Shen L, Ellis L, Sotomayor P, Swetzig W, Huang R, Conroy D, Orillion A, Das G, Pili R. Ramakrishnan S, et al. Among authors: pili r. BMC Cancer. 2016 Aug 9;16:617. doi: 10.1186/s12885-016-2604-7. BMC Cancer. 2016. PMID: 27506904 Free PMC article.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA. Pili R, et al. Br J Cancer. 2017 Mar 28;116(7):874-883. doi: 10.1038/bjc.2017.33. Epub 2017 Feb 21. Br J Cancer. 2017. PMID: 28222071 Free PMC article. Clinical Trial.
227 results